Image Description

INVESTORS
& MEDIA

circle

Press Release

  View printer-friendly version

<<  Back

Cytokinetics Announces Clinical Trials Data Relating to CK-1827452 to be Presented at the 2009 Annual Scientific Sessions of the American College of Cardiology

Company Plans Investor Teleconference to Discuss Final Results
SOUTH SAN FRANCISCO, CA, Mar 23, 2009 (MARKET WIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to a Phase IIa clinical trial for CK-1827452 are scheduled to be presented at the 2009 Annual Scientific Sessions of the American College of Cardiology, which is being held March 29-31, 2009 at the Orange Country Convention Center, Orlando, FL. These data represent the final results from this completed Phase IIa clinical trial evaluating CK-1827452 in stable heart failure patients. CK-1827452 is a novel cardiac myosin activator being developed for the potential treatment of patients with either acutely decompensated or chronic heart failure.

Poster Presentation at the Annual Scientific Session of the American College of Cardiology

Poster #1024-196: "The Selective Cardiac Myosin Activator, CK-1827452, Increases Systolic Function in a Concentration-Dependent Manner in Patients with Stable Heart Failure" will be presented in a poster session entitled "Myocardial Function/Heart Failure-Clinical Pharmacological Treatment" on Sunday, March, 29, 2009, from 1:30 p.m. - 4:30 p.m. Eastern Time in West Hall D, Orange Country Convention Center. The presentation will be moderated from 3:30 p.m. to 4:30 p.m. by Roxy Senior, MD, DM, FRCP, FESC, FACC, Director of Cardiac Research, Northwick Park Hospital, Middlesex Harrow, United Kingdom.

Cytokinetics Conference Call and Webcast

Cytokinetics plans to host a conference call and webcast on Monday, March 30th from 8:30 a.m. - 9:30 a.m. Eastern Time to discuss the results from this Phase IIa clinical trial. Robert Blum, Cytokinetics' President and Chief Executive Officer, will be joined by Andrew Wolff, MD, FACC, Cytokinetics' Senior Vice President of Clinical Research and Development and Chief Medical Officer, Fady Malik, MD, Cytokinetics' Vice President of Muscle Biology and Cardiovascular Therapeutics and John R. Teerlink, MD, FACC, FAHA, FESC, Professor of Medicine at the University of California, San Francisco and the Director of Heart Failure at the San Francisco Veterans Affairs Medical Center, in a discussion of the data. Mr. Blum will moderate the session. Dr. Wolff will review the Phase IIa clinical trial design and results and plans for the future clinical development of CK-1827452, with Drs. Malik and Teerlink offering additional perspectives on the clinical relevance of these data and the potential of CK-1827452 for the treatment of heart failure patients.

The conference call and accompanying slides will be simultaneously webcast and can be accessed in the Investor Relations section of Cytokinetics' website at www.cytokinetics.com. The live audio of the conference call is also accessible via telephone to investors, members of the news media and the general public by dialing either (866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078 (International) and typing in the passcode 91861227.

An archived replay of the webcast will be available via Cytokinetics' website until April 13, 2009. The replay will also be available via telephone by dialing (800) 642-1687 (United States and Canada) or (706) 645-9291 (International) and typing in the passcode 91861227 from March 30, 2009 at 12:30 p.m. Eastern Time until April 13, 2009.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' cardiac muscle contractility program is focused on cardiac muscle myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics' lead compound from this program, CK-1827452, a novel small molecule cardiac muscle myosin activator, is in Phase II clinical trials for the treatment of heart failure. Amgen Inc. has obtained an option for an exclusive license to develop and commercialize CK-1827452, subject to Cytokinetics' development and commercialization participation rights. In April 2008, Cytokinetics announced the selection of a potential drug candidate, CK-2017357, directed towards skeletal muscle contractility which may be developed as a potential treatment for diseases and medical conditions associated with skeletal muscle weakness. In January 2009, Cytokinetics announced the selection of a potential drug candidate directed towards smooth muscle contractility which may be developed as a potential treatment for diseases associated with pulmonary arterial hypertension and bronchoconstriction.

Cytokinetics' cancer program is focused on mitotic kinesins, a family of motor proteins essential to cell division. Cytokinetics is developing two drug candidates that have arisen from this program, ispinesib and SB-743921, each an inhibitor of kinesin spindle protein. In addition, Cytokinetics and GlaxoSmithKline are conducting research and development activities focused on GSK-923295, an inhibitor of centromere-associated protein E.

All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development programs, planned presentations relating to the results from Cytokinetics' clinical trials with CK-1827452 and the potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval, production and marketing of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development, product approval or market acceptance, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Contact:
Christopher S. Keenan
Director, Investor Relations and Media
(650) 624-3000

SOURCE: Cytokinetics, Inc.